Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women

Overview

The primary objective of this study is to compare blood loss resulting from surgical termination of pregnancy up to 12 weeks gestation between women who are anticoagulated to therapeutic levels and those who are not anticoagulated. This study is based on the hypothesis that anticoagulant therapy does not increase intraoperative blood loss in women receiving surgical abortions up to 12 weeks gestation.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2010

Detailed Description

We intend to conduct a prospective cohort study at Oregon Health and Science University and the University of Hawaii. This study will not be blinded and subjects will not be randomized. Women will be approached about this study after they have made a decision to terminate the pregnancy and have completed the preoperative history and physical examination and surgical consenting process. For patients who are receiving anticoagulant medications, the decision to continue anticoagulant therapy or interrupt it will be made by the patient's physician, independently of this study. We will recruit women who continue on anticoagulant therapy (heparin, low molecular weight heparin, or warfarin) without interruption for the surgical procedure. Our control group will consist of women who are not on anticoagulant treatment. This is a matched study and our control group will be matched for gestational age, parity, and cesarean section history.

Arms, Groups and Cohorts

  • 1
    • Women who are anticoagulated.
  • 2
    • Matched case controls.

Clinical Trial Outcome Measures

Primary Measures

  • Volume of Intraoperative Blood Loss
    • Time Frame: Post procedure
    • Quantitative blood loss using volume measurement and weight

Participating in This Clinical Trial

Inclusion Criteria

  • Female seeking abortion services – Less than or equal to 12 weeks gestation – Age 18-50 – Willing and able to sign informed consent – Use of Coumadin or LMW heparin (treatment group only) Exclusion Criteria:

  • Unwilling or unable to sign informed consent – Women taking daily aspirin or herbal therapies containing gingko biloba – Women with a known history of a bleeding disorder such as von willebrand's disease

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Hawaii
  • Collaborator
    • Oregon Health and Science University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Bliss Kaneshiro, Associate Professor – University of Hawaii
  • Overall Official(s)
    • Bliss Kaneshiro, M.D., Principal Investigator, University of Hawaii
    • Alison Edelman, M.D., M.P.H., Principal Investigator, Oregon Health and Science University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.